Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 PRESENTED AND PUBLISHED THE POSITIVE RESULTS FROM BOTH THE LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS AT SCIENTIFIC MEETINGS AND IN JAMA AND NEJM   PRE-NDA MEETING SCHEDULED TO TAKE PLACE IN 4Q 2025   EXPLORE-CKD PHASE 2 TRIAL SUCCESSFULLY ACHIEVED STATISTICAL SIGNIFICANCE IN REDUCTION OF SYSTOLIC BP AND UACR, AND DEMONSTRATED A FAVORABLE SAFETY PROFILE   EXPLORE-OSA PHASE 2 TRIAL IN OSA PARTICIPANTS WITH HYPERTENSION IS ONGOING; TOPLINE RESULTS ANTICIPATED IN 1H 2026   CONFERENCE CALL TODAY AT 4:30 P.M. ET  RADNOR, PA.

MINERALYS THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

RADNOR, PA., AUG. 04, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS HYPERTENSIVE NEPHROPATHY, OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED IT WILL REPORT ITS FINANCIAL RESULTS FROM THE SECOND QUARTER ENDED JUNE 30, 2025, AFTER THE FINANCIAL MARKETS CLOSE ON TUESDAY, AUGUST 12, 2025.

MINERALYS THERAPEUTICS TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON TUESDAY, AUGUST 12, 2025

 THE LAUNCH-HTN TRIAL IS THE LARGEST TRIAL OF AN ALDOSTERONE SYNTHASE INHIBITOR COMPLETED IN PARTICIPANTS WITH UNCONTROLLED OR TREATMENT RESISTANT HYPERTENSION 

MINERALYS THERAPEUTICS ANNOUNCES JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA) PUBLICATION OF PIVOTAL PHASE 3 LAUNCH-HTN TRIAL FOR LORUNDROSTAT

 EXPLORE-CKD MET ITS PRIMARY ENDPOINT; LORUNDROSTAT 25 MG ONCE DAILY ACHIEVED A 9.3 MMHG REDUCTION IN SYSTOLIC BLOOD PRESSURE, AND A 7.5 MMHG PLACEBO-ADJUSTED REDUCTION (P=0.0024) AT FOUR WEEKS   LORUNDROSTAT SHOWED A CLINICALLY MEANINGFUL REDUCTION IN THE PRE-DEFINED ENDPOINT SPOT URINE ALBUMIN-TO-CREATININE RATIO OF 31% (P6.0 MMOL/L) 0/59 (0%) 3/58 (5%)  BP, BLOOD PRESSURE; UACR, URINE ALBUMIN-TO-CREATININE RATIO; TEAE, TREATMENT-EMERGENT ADVERSE EVENT * PRIMARY ENDPOINT. ** CYSTATIN-C FORMULA, A SURROGATE BIOMARKER OF RENAL FUNCTION NOT SUBJECT TO MATE1 TRANSPORT AND ELIMINATION IN THE GLOMERULI OF THE KIDNEY.

MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 EXPLORE-CKD TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS WITH CKD AND ALBUMINURIA

 LARGEST HYPERTENSION TRIAL OF AN ALDOSTERONE SYNTHASE INHIBITOR TO DATE DEMONSTRATED THE EFFICACY OF LORUNDROSTAT IN OVER 1,000 PARTICIPANTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION IN A REAL-WORLD SETTING 

MINERALYS THERAPEUTICS ANNOUNCES LATE-BREAKING PRESENTATION OF DATA FROM THE LAUNCH-HTN PIVOTAL TRIAL OF LORUNDROSTAT IN UNCONTROLLED OR RESISTANT HYPERTENSION AT 34TH EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION (ESH 2025)

RADNOR, PA., MAY 20, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION, CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED THAT DATA FROM THE PIVOTAL PHASE 3 LAUNCH-HTN TRIAL EVALUATING THE EFFICACY AND SAFETY OF LORUNDROSTAT FOR THE TREATMENT OF UNCONTROLLED HYPERTENSION (UHTN) OR RESISTANT HYPERTENSION (RHTN) WILL BE PRESENTED IN A LATE-BREAKING CLINICAL TRIALS SESSION AT THE 34TH EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION (ESH 2025), WHICH WILL BE HELD IN MILAN AT THE MICO CONGRESS CENTER, ON MAY 23-26, 2025.

MINERALYS THERAPEUTICS ANNOUNCES LATE-BREAKING PRESENTATION OF PHASE 3 LAUNCH-HTN TRIAL AT 34TH EUROPEAN MEETING ON HYPERTENSION AND CARDIOVASCULAR PROTECTION

 PIVOTAL ADVANCE-HTN AND LAUNCH-HTN TRIALS SUCCESSFULLY ACHIEVED STATISTICAL SIGNIFICANCE IN PRIMARY EFFICACY ENDPOINTS AND DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE   ANTICIPATE EXPLORE-CKD PHASE 2 TRIAL TO DELIVER TOPLINE DATA IN Q22025   INITIATED EXPLORE-OSA PHASE 2 TRIAL IN Q1 2025   CONFERENCE CALL TODAY AT 4:30 P.M. ET  RADNOR, PA.

MINERALYS THERAPEUTICS REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

RADNOR, PA., MAY 07, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION, CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED THAT MANAGEMENT WILL BE PARTICIPATING IN THE BANK OF AMERICA SECURITIES 2025 HEALTH CARE CONFERENCE BEING HELD IN LAS VEGAS ON MAY 12-15, 2025.

MINERALYS THERAPEUTICS TO PARTICIPATE IN THE BANK OF AMERICA SECURITIES HEALTH CARE CONFERENCE

RADNOR, PA., MAY 05, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION, CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED IT WILL REPORT ITS FINANCIAL RESULTS FROM THE FIRST QUARTER ENDED MARCH 31, 2025, AFTER THE FINANCIAL MARKETS CLOSE ON MONDAY, MAY 12, 2025.

MINERALYS THERAPEUTICS TO ANNOUNCE FIRST QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON MONDAY, MAY 12, 2025

 SIGNIFICANT BLOOD PRESSURE REDUCTIONS AMONG PATIENTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION TREATED WITH LORUNDROSTAT REINFORCE KEY ROLE OF DYSREGULATED ALDOSTERONE IN DISEASE ONSET AND PROGRESSION 

MINERALYS THERAPEUTICS ANNOUNCES PUBLICATION OF PIVOTAL PHASE 2 ADVANCE-HTN RESULTS IN THE NEW ENGLAND JOURNAL OF MEDICINE (NEJM)

 LORUNDROSTAT 50 MG DOSE ACHIEVED A 15.4 MMHG ABSOLUTE REDUCTION AND 7.9 MMHG PLACEBO-ADJUSTED REDUCTION (P=0.001), ASSESSED BY 24HR ABPM AT WEEK 12, WITH FAVORABLE SAFETY AND TOLERABILITY PROFILE 

MINERALYS THERAPEUTICS ANNOUNCES LATE-BREAKING DATA FROM ADVANCE-HTN PIVOTAL TRIAL OF LORUNDROSTAT IN UNCONTROLLED AND RESISTANT HYPERTENSION PRESENTED AT THE AMERICAN COLLEGE OF CARDIOLOGY'S ANNUAL SCIENTIFIC SESSION & EXPO (ACC.25)

Mineralys Therapeutics, Inc.

MLYS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Mineralys Therapeutics, Inc.

MLYS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MLYS